News
-
Respivant Sciences has announced dosing of the first patient in the Phase 2b SCENIC trial of its RVT-1601 cromolyn sodium inhalation solution for the treatment of cough in idiopathic pulmonary fibrosis (IPF) patients. Respivant was… Read more . . .
-
UCB said that the FDA has approved an NDA for Nayzilam midazolam nasal spray (formerly USL261) for the treatment of seizure clusters in epilepsy patients aged and older. UCB acquired the nasal spray from former… Read more . . .
-
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting… Read more . . .
-
Aptar Pharma has announced that GSK’s Otrivin xylometazoline nasal spray, which is delivered via Aptar’s Freepod multidose nasal spray pump, won a 2019 WorldStar Packaging Award in the Medical & Pharma category. The WorldStar Packaging… Read more . . .
-
Lonza has announced the launch of a new DPI capsule portfolio called Capsugel Zephyr “to meet the growing need for customized solutions for optimal pulmonary drug delivery.” The new DPI capsules are customizable and can… Read more . . .
-
Over 500 OINDP specialists attended RDD Europe 2019 in Estoril, Portugal, May 7-10, making the conference the biggest RDD Europe meeting ever, the organizers said. Carolyn Penot of Aptar Pharma, which co-organizes RDD Europe said,… Read more . . .
-
Robert Clarke is stepping down as CEO of DPI developer Pulmatrix and will be succeeded immediately by current Chief Business Officer Ted Raad, the company said. Clarke, who was appointed CEO in 2012, will stay… Read more . . .
-
Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma’s digital soft mist inhaler. Pneuma… Read more . . .
-
Etripamil developer Milestone Pharmaceuticals announced that its recently closed initial public offering raised approximately $82.5 million gross by selling 5,500,000 common shares at $15/share. The company is developing intranasal etripamil for the treatment of paroxysmal… Read more . . .
-
Glenmark Pharmaceuticals recently said that a Phase 3 study comparing Ryaltris olopatadine hydrochloride to placebo in seasonal allergic rhinitis patients aged 6 up to 12 years achieved its primary endpoint. The 14-day study, which enrolled… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.